WO2005106011A3 - Process for preparing dipeptidyl iv inhibitors and intermediates therefor - Google Patents

Process for preparing dipeptidyl iv inhibitors and intermediates therefor Download PDF

Info

Publication number
WO2005106011A3
WO2005106011A3 PCT/US2005/012615 US2005012615W WO2005106011A3 WO 2005106011 A3 WO2005106011 A3 WO 2005106011A3 US 2005012615 W US2005012615 W US 2005012615W WO 2005106011 A3 WO2005106011 A3 WO 2005106011A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
boc
acid
treating
intermediates therefor
Prior art date
Application number
PCT/US2005/012615
Other languages
French (fr)
Other versions
WO2005106011A2 (en
Inventor
Michael Politino
Matthew M Cadin
Paul M Skonezny
Jason G Chen
Original Assignee
Bristol Myers Squibb Co
Michael Politino
Matthew M Cadin
Paul M Skonezny
Jason G Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0509890-4A priority Critical patent/BRPI0509890A/en
Application filed by Bristol Myers Squibb Co, Michael Politino, Matthew M Cadin, Paul M Skonezny, Jason G Chen filed Critical Bristol Myers Squibb Co
Priority to CA002563903A priority patent/CA2563903A1/en
Priority to EP05735335A priority patent/EP1737970A4/en
Priority to AU2005238442A priority patent/AU2005238442A1/en
Priority to CN2005800195121A priority patent/CN1968925B/en
Priority to JP2007508513A priority patent/JP4896872B2/en
Publication of WO2005106011A2 publication Critical patent/WO2005106011A2/en
Priority to IL178520A priority patent/IL178520A0/en
Publication of WO2005106011A3 publication Critical patent/WO2005106011A3/en
Priority to KR1020067023783A priority patent/KR101269813B1/en
Priority to NO20065191A priority patent/NO20065191L/en
Priority to NO20151145A priority patent/NO20151145L/en
Priority to NO20151146A priority patent/NO20151146L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C12N1/066—Lysis of microorganisms by physical methods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0016—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1)
    • C12N9/0018—Phenylalanine dehydrogenase (1.4.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • C12P13/222—Phenylalanine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P15/00—Preparation of compounds containing at least three condensed carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/02—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a cytochrome as acceptor (1.2.2)
    • C12Y102/02001—Formate dehydrogenase (cytochrome) (1.2.2.1)

Abstract

A process for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV is provided which employs a BOC-protected amine of the structure (3) prepared by subjecting an acid of the structure (1) to reduce amination by treating the acid with ammonium formate, nicotinamide adenine dinucleotide, dithiothreitol and partially purified phenylalanine dehydrogenase/formate dehydrogenase enzyme concentrate (PDH/FDH) and without isolating treating the resulting amine of the structure (2) with di-tert-butyl dicarbonate to form the BOC-protected amine.
PCT/US2005/012615 2004-04-14 2005-04-13 Process for preparing dipeptidyl iv inhibitors and intermediates therefor WO2005106011A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2007508513A JP4896872B2 (en) 2004-04-14 2005-04-13 Process for producing dipeptidyl peptidase IV inhibitor and intermediate thereof
CA002563903A CA2563903A1 (en) 2004-04-14 2005-04-13 Process for preparing dipeptidyl iv inhibitors and intermediates therefor
EP05735335A EP1737970A4 (en) 2004-04-14 2005-04-13 Process for preparing dipeptidyl iv inhibitors and intermediates therefor
AU2005238442A AU2005238442A1 (en) 2004-04-14 2005-04-13 Process for preparing dipeptidyl IV inhibitors and intermediates therefor
CN2005800195121A CN1968925B (en) 2004-04-14 2005-04-13 Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
BRPI0509890-4A BRPI0509890A (en) 2004-04-14 2005-04-13 process for preparing dipeptidyl peptidase iv inhibitors and intermediates therefor
IL178520A IL178520A0 (en) 2004-04-14 2006-10-15 Process for preparing dipeptidyl peptidase iv inhibitors and intermediates therefor
NO20065191A NO20065191L (en) 2004-04-14 2006-11-13 Process for the preparation of dipeptidyl IV inhibitors and intermediates thereof
KR1020067023783A KR101269813B1 (en) 2004-04-14 2006-11-13 Process for preparing dipeptidyl iv inhibitors and intermediates therefor
NO20151145A NO20151145L (en) 2004-04-14 2015-09-07 Process for the preparation of dipeptidyl IV inhibitors and their intermediates
NO20151146A NO20151146L (en) 2004-04-14 2015-09-07 Process for the preparation of dipeptidyl IV inhibitors and their intermediates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56198604P 2004-04-14 2004-04-14
US60/561,986 2004-04-14

Publications (2)

Publication Number Publication Date
WO2005106011A2 WO2005106011A2 (en) 2005-11-10
WO2005106011A3 true WO2005106011A3 (en) 2006-10-26

Family

ID=35242266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012615 WO2005106011A2 (en) 2004-04-14 2005-04-13 Process for preparing dipeptidyl iv inhibitors and intermediates therefor

Country Status (16)

Country Link
US (4) US7741082B2 (en)
EP (3) EP2894227A3 (en)
JP (3) JP4896872B2 (en)
KR (1) KR101269813B1 (en)
CN (3) CN103215320B (en)
AR (1) AR048695A1 (en)
AU (1) AU2005238442A1 (en)
BR (1) BRPI0509890A (en)
CA (1) CA2563903A1 (en)
IL (1) IL178520A0 (en)
NO (3) NO20065191L (en)
PE (1) PE20060255A1 (en)
RU (1) RU2373194C2 (en)
TW (1) TW200540274A (en)
WO (1) WO2005106011A2 (en)
ZA (1) ZA200608304B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7420079B2 (en) * 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US7741082B2 (en) * 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
WO2007085933A2 (en) * 2006-01-25 2007-08-02 Glenmark Pharmaceuticals Limited Process for the preparation of n-[1-(s)-ethoxycarbonyl-1-butyl]-(s)-alanine-dmt complex and its use in the preparation of perindopril
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
PE20090696A1 (en) 2007-04-20 2009-06-20 Bristol Myers Squibb Co CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM
PE20090938A1 (en) 2007-08-16 2009-08-08 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
PE20110297A1 (en) 2008-08-15 2011-05-26 Boehringer Ingelheim Int DPP-4 INHIBITORS FOR WOUND HEALING
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (en) 2009-01-29 2015-01-01 Boehringer Ingelheim Int Treatment for diabetes in paediatric patients
CA2752437C (en) 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
NZ594487A (en) 2009-02-13 2013-11-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
EP2417260A1 (en) 2009-04-08 2012-02-15 Bristol-Myers Squibb Company A genetically stable plasmid expressing pdh and fdh enzymes
MY145258A (en) * 2009-07-06 2012-01-11 Univ Sains Malaysia A system for producing l-homophenylalanine and a process for producing l-homophenylalanine
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
FR2956400A1 (en) * 2010-02-15 2011-08-19 Finorga PROCESS FOR THE PREPARATION OF ADAMANTYL COMPOUNDS
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
JP5373996B2 (en) 2010-05-05 2013-12-18 アッシア・ケミカル・インダストリーズ・リミテッド Saxagliptin intermediates, saxagliptin polymorphs and methods for their preparation
JP6034781B2 (en) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
EP2611770A1 (en) 2010-09-03 2013-07-10 Sandoz AG Process for the reductive amination of -keto carboxylic acids
WO2012047871A1 (en) 2010-10-04 2012-04-12 Assia Chemical Industries Ltd Polymorphs of saxagliptin hydrochloride and processes for preparing them
WO2013059817A1 (en) * 2011-10-21 2013-04-25 Murer Kenneth H Buoyancy-based cervical traction system
JPWO2013081100A1 (en) * 2011-11-30 2015-04-27 積水メディカル株式会社 Adamantyl hydantoin compounds
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
AU2013285078A1 (en) 2012-07-02 2015-01-29 Sun Pharmaceutical Industries Limited Saxagliptin salts
CN103539724B (en) * 2012-07-12 2017-09-26 博瑞生物医药（苏州）股份有限公司 The novel crystal forms and purification process of BMS-477118 single stereoisomers
WO2014108830A1 (en) 2013-01-10 2014-07-17 Wockhardt Limited A process for preparing pharmaceutically acceptable salt of saxagliptin
CN103265473A (en) * 2013-06-04 2013-08-28 上海同昌生物医药科技有限公司 Method for producing saxagliptin
ITMI20131029A1 (en) * 2013-06-20 2014-12-21 Chemelectiva S R L USEFUL INTERMEDIATES FOR THE PREPARATION OF SAXAGLIPTINA
CN103555683B (en) * 2013-11-19 2015-11-18 南京博优康远生物医药科技有限公司 A kind of synthetic method of saxagliptin chiral intermediate
WO2015087262A1 (en) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Process for the preparation of saxagliptin and its intermediates
CN103724254A (en) * 2013-12-23 2014-04-16 上海应用技术学院 Preparation method of saxagliptin intermediate
CN105315189A (en) * 2014-05-29 2016-02-10 上海医药工业研究院 (5S)-5-aminocarbonyl-4,5-dihydro-1H-pyrrole-1-carboxylic acid-1(1,1-dimethylethyl)ester preparation method
CN104098505A (en) * 2014-07-31 2014-10-15 天津民祥生物医药科技有限公司 Preparation method for saxagliptin
CN104177284B (en) * 2014-08-01 2016-08-24 常州大学 The method of synthesis 3-azabicyclic [3,1,0] hexyl-1-formaldehyde
CN104293844B (en) * 2014-08-26 2017-10-10 苏州永健生物医药有限公司 A kind of synthetic method of Telaprevir intermediate
CN104356048B (en) * 2014-11-02 2016-08-24 浙江医药高等专科学校 Cyclohexane-carboxylic acid amide derivatives, Preparation Method And The Use
CN104356046B (en) * 2014-11-02 2017-04-05 浙江医药高等专科学校 Cyclohexane-carboxylic acid amide derivatives that cycloalkyl replaces and application thereof
BR112017019170A2 (en) 2015-03-09 2018-07-10 Intekrin Therapeutics, Inc. Methods for treating non-alcoholic fatty liver disease and / or lipodystrophy
CN105130879B (en) * 2015-07-24 2018-03-02 沧州那瑞化学科技有限公司 （R）The preparation method of 3 Boc amino piperidines
CN106554301B (en) * 2015-09-30 2018-09-21 深圳翰宇药业股份有限公司 A kind of preparation method of saxagliptin key intermediate
CN106755152B (en) * 2017-01-23 2020-06-16 苏州引航生物科技有限公司 Method for preparing augustine intermediate
JP2020515639A (en) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド PPARγ agonists for the treatment of progressive supranuclear palsy
CN109970620B (en) * 2017-12-27 2022-07-12 江苏威凯尔医药科技有限公司 Method for preparing saxagliptin intermediate
RU2712097C1 (en) * 2018-09-28 2020-01-24 Общество с ограниченной ответственностью "Необиотек" Dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes mellitus, compounds (versions)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1023896A (en) * 1996-05-07 1998-01-27 Unitika Ltd Recombinant plasmid, escherichia coli transformed thereby, cultured product from the escherichia coli and production of amino acid or derivative therefrom using the same
IL120873A0 (en) 1996-05-24 1997-09-30 Tanabe Seiyaku Co Process for preparing optically active 2-halogen-3-hydroxypropionic acid ester
US6068991A (en) * 1997-12-16 2000-05-30 Bristol-Myers Squibb Company High expression Escherichia coli expression vector
IL140898A0 (en) 1998-07-15 2002-02-10 Bristol Myers Squibb Co A process for preparing an alkylamino acid compound and new keto carboxylic acid derivatives
ATE431422T1 (en) 2000-08-16 2009-05-15 Bristol Myers Squibb Co STEREOSELECTIVE REDUCTION OF SUBSTITUTED OXO-BUTANES
US6828119B2 (en) 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
ES2307746T3 (en) 2001-04-03 2008-12-01 Bristol-Myers Squibb Company OCHROBACTRUM ANTHROPI 'D-HYDANTOINASE.
WO2003054155A2 (en) * 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
US7420079B2 (en) * 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
TW200538122A (en) 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
TW200536827A (en) 2004-05-04 2005-11-16 Bristol Myers Squibb Co Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
US7214702B2 (en) 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Also Published As

Publication number Publication date
US20100291642A1 (en) 2010-11-18
NO20065191L (en) 2006-11-13
EP3000893A3 (en) 2016-06-29
KR101269813B1 (en) 2013-05-30
CN1968925B (en) 2013-04-17
JP4896872B2 (en) 2012-03-14
EP3000893A2 (en) 2016-03-30
ZA200608304B (en) 2008-07-30
EP2894227A3 (en) 2015-08-12
US8222009B2 (en) 2012-07-17
JP2007532137A (en) 2007-11-15
KR20070006903A (en) 2007-01-11
US7741082B2 (en) 2010-06-22
WO2005106011A2 (en) 2005-11-10
CN1968925A (en) 2007-05-23
JP5715169B2 (en) 2015-05-07
IL178520A0 (en) 2007-02-11
CN103215321A (en) 2013-07-24
JP5210406B2 (en) 2013-06-12
RU2373194C2 (en) 2009-11-20
BRPI0509890A (en) 2007-10-30
EP1737970A2 (en) 2007-01-03
CN103215320A (en) 2013-07-24
EP1737970A4 (en) 2011-08-24
EP2894227A2 (en) 2015-07-15
AR048695A1 (en) 2006-05-17
CN103215321B (en) 2015-09-09
AU2005238442A1 (en) 2005-11-10
US8809024B2 (en) 2014-08-19
JP2013121351A (en) 2013-06-20
US20130204012A1 (en) 2013-08-08
US8361761B2 (en) 2013-01-29
US20120276600A1 (en) 2012-11-01
PE20060255A1 (en) 2006-03-31
CA2563903A1 (en) 2005-11-10
RU2006140134A (en) 2008-05-27
TW200540274A (en) 2005-12-16
CN103215320B (en) 2015-09-23
NO20151145L (en) 2006-11-13
US20050260712A1 (en) 2005-11-24
JP2011177177A (en) 2011-09-15
NO20151146L (en) 2006-11-13

Similar Documents

Publication Publication Date Title
WO2005106011A3 (en) Process for preparing dipeptidyl iv inhibitors and intermediates therefor
Fuchs et al. Chemoenzymatic asymmetric total synthesis of (S)-Rivastigmine using ω-transaminases
SG158905A1 (en) Methods for the production of ansamitocins
TW200604150A (en) Method for producing (meth)acrylate derivative having isocyanate group
WO2008108998A8 (en) Method to increase the yield and improve purification of products from transaminase reactions
UA88474C2 (en) Process for preparation a product sugar stream from cellulosic biomass
MY141797A (en) Biochemical synthesis of 6-amino caproic acid
IL200692A0 (en) Method of preparing a desired diastereomer of a tetrahydro-??-carboline and use thereof for preparing an indole-1,4-dione derivative
NO20071866L (en) Processes for protecting optically active amine derivatives
UA100964C2 (en) Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
WO2009102155A3 (en) Process for preparation of 2-methyl-2´-phenylpropionic acid derivatives and novel intermediate compounds
EP1477481A4 (en) Process for producing quinazolin-4-one derivative
PE20060307A1 (en) ENZYME AMONOLYSIS PROCESS FOR THE PREPARATION OF INTERMEDIARY COMPOUNDS FOR INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
EP2103601A4 (en) Process for production of phenylalanine derivatives having quinazolinedione skeletons and intermediates for the production
PL1851322T3 (en) Method for the enantioselective enzymatic reduction of keto compounds
DE602005024776D1 (en) METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO ACIDS USING A WHOLE CELL CATALYST
WO2004101803A3 (en) Process for producing anticancer agent ll-d45042
IL187640A0 (en) Method for preparing clopidogrel and intermediates used therein
DK0904348T3 (en) Process for the preparation of amino alcohols and derivatives thereof
WO2012161522A3 (en) Microorganism found in the corynebacterium genus having enhanced l-ornithine production and method for preparing l-ornithine using same
WO2009025238A1 (en) Method for producing quinazoline derivative
WO2003000910A3 (en) Metabolic controlled fermentation process for pseudomonic acid production
CA2494854A1 (en) Methods to produce theanine
TW200636072A (en) A method for producing l-lactic acid
TW200745341A (en) A method for preparing cercosporamide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006/08304

Country of ref document: ZA

Ref document number: 200608304

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005735335

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/011735

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 5914/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 06103461

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2005238442

Country of ref document: AU

Ref document number: 2563903

Country of ref document: CA

Ref document number: 2007508513

Country of ref document: JP

Ref document number: 5966/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 178520

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005238442

Country of ref document: AU

Date of ref document: 20050413

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005238442

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067023783

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006140134

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580019512.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005735335

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067023783

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0509890

Country of ref document: BR